奥西替尼对非小细胞肺癌伴脑部转移患者的疗效观察

Therapeutic effects of oxitinib on non-small cell lung cancer accompanied by brain metastases

目的探究奥西替尼对非小细胞肺癌伴有脑部转移患者的临床疗效。方法搜集2018年1月至2019年7月接收治疗的晚期非小细胞肺癌伴脑转移的38例患者作为研究对象。研究对象按照入院先后顺序分为对照组和试验组。对照组患者采用传统药物治疗,试验组患者规范使用服用奥西替尼,2组患者同时接受相同放疗方案,观察2组疗效情况。结果对照组和试验组患者治疗前后对比分析,癌胚抗原(CEA)、血管内皮生长因子(VEGF)的含量均有明显下降,差异有统计学意义(P<0.05);但试验组患者治疗后CEA以及VEGF的含量下降程度更加明显,差异有统计学意义(P<0.05)。治疗后试验组患者脑部肿瘤长径明显短于对照组(P<0.05),2组患者治疗期间不良事件发生率差异无统计学意义(P>0.05)。结论奥西替尼对非小细胞肺癌伴有脑部转移患者治疗效果明显,且不良事件发生率和传统药物基本保持一致,值得进一步研究或推广。

Objective To investigate the therapeutic effects of oxitinib on non-small cell lung cancer accompanied by brain metastases.Methods A total of 38 patients with advanced non-small cell lung cancer complicated by brain metastasis who were treated in our hospital from January 2018 to July 2019 were enrolled as research subjects,who were divided into control group and experimental group according to the order of admission.The patients in control group were treated by traditional medicines,however,the patients in experimental group were treated by oral oxitinib.The patients in both groups received the same radiotherapy scheme,and the curative effects were observed and compared between the two groups.Results After treatment,the levels of carcinoembryonic antigen CEA and vascular endothelial growth factor VEGF were significantly decreased in both groups(P<0.05),moreover,the decrease degree in experimental group was more significant than that in control group(P<0.05).Moreover the brain tumor long diameter in experimental group was significantly shorter than that in control group after treatment.There was no significant difference in the incidence rate of adverse events during treatment between the two groups(P>0.05).Conclusion Oxitinib has obvious therapeutic effects on non-small cell lung cancer complicatyed by brain metastasis,and the incidence rate of adverse events is basically the same as that of medication with traditional drugs,therefor,which deserves further research and promotion.